FDA withdraws coronavirus emergency use authorization for hydroxychloroquine

Hydroxychloroquine.
(Image credit: GEORGE FREY/AFP via Getty Images)

At the request of Gary Disbrow, the acting director of the Biomedical Advanced Research and Development Authority, the Food and Drug Administration on Monday withdrew emergency use authorizations for hydroxychloroquine and chloroquine related to coronavirus treatment.

The authorizations were controversial, as many skeptics believed they were made because President Trump had touted the malaria drugs as effective treatments against COVID-19, despite researchers concerns about potential heart-related side effects. Ultimately, after reviewing new information from large clinical trials, the FDA said it does not believe the drugs are likely "to produce an antiviral effect" against the novel virus.

Hydroxychloroquine is approved for several uses like treating arthritis and lupus, so doctors could still use it "off label" to treat coronavirus patients, and clinical trials examining its effect against COVID-19 can continue, Politico reports. The version of chloroquine temporarily authorized by the FDA, however, is not approved in the U.S., so all use of it will end. Read more at Politico.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up

Continue reading for free

We hope you're enjoying The Week's refreshingly open-minded journalism.

Subscribed to The Week? Register your account with the same email as your subscription.

Tim O'Donnell

Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.